Acta Biomedica Scientia

STUDY ON THERAPEUTIC APPROACH AND ITS OUTCOME WITH PROKINETICS AMONG DIABETES PATIENTS

Swetha K*, Krishna chaitanya T, Tejaswi L, Thriveni P

swethakothuri234@gmail.com

Gerd, Peptic Ulcers, Gastritis, Gastroparesis, Prokinetics.

Gastroparesis is a chronic, symptomatic disorder of the stomach that is characterized by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis literally translated means “stomach paralysis. Gastroparesis is a digestive disorder in which the motility of the stomach is either abnormal or absent. In health, when the stomach is functioning normally, contractions of the stomach help to crush ingested food and then propel the pulverized food into the small intestine where further digestion and absorption of nutrients occurs. When the condition of Gastroparesis is present the stomach is unable to contract normally, and therefore cannot crush food nor propel food into the small intestine properly. Normal digestion may not occur. To study the demographic details and social history of diabetic induced gastropathy patients and need of the prokinetic agent. To find out how effective the prokinetic works in DM patient. To evaluate and compare the effectiveness of each prokinetic agent with lifestyle modifications and without the lifestyle modifications. A patient-based instrument called the gastroparesis cardinal symptom index (GCSI) has been developed to assess the severity of gastroparesis. The GCSI index is based on 3 symptom subscales 1.Nausea/vomiting [nausea, vomiting, retching’s] 2.Postprandial fullness [not able to finish full meals, stomach fullness, loss of appetite, feeling excessively after meals] 2.Bloating[bloating, belly visible extremely large] of a larger upper gastrointestinal disorders– symptom severity index that was previously developed. These 3 scales were selected as part of the GCSI because they assess common symptoms related to gastroparesis- nausea/vomiting, postprandial fullness/early satiety, and bloating. The GCSI issued to rate symptom change by either the physician or the patient over a 2-6 week recall period. The scale was mention below (table 1). The findings of this study indicate that the GCSI is a reliable and valid instrument for measuring symptom severity in patients with gastroparesis. The patients who used prokinetics named itopride, levosulpiride, acotinamide who diagnosed with diabetic gastroparesis showed significant improvement in the symptoms